How Bio-Techne's Spatial Biology COMET Expansion (TECH) Has Changed Its Investment Story
Bio-Techne recently expanded its COMET spatial biology portfolio with new SPYRE Focus Panels, SPYRE Amplification Kits, and upgraded HORIZON image analysis software. This move aims to enhance automated, modular tissue analysis and deepen the company's high-content spatial biology offerings. While this expansion reinforces Bio-Techne's long-term investment narrative focused on specialized tools, near-term challenges such as funding pressures in biotech and academia remain, making execution on higher-margin platforms crucial for earnings growth.
Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. (TECH) stock saw a 1.26% increase, closing at $53.80, outperforming the broader market indices like the S&P 500 and Dow Jones Industrial Average. This positive movement occurred during an overall strong trading session. Despite the rally, the stock remains 25.44% below its 52-week high reached earlier in the year.
Evercore Maintains Bio-Techne(TECH.US) With Hold Rating, Cuts Target Price to $54
Evercore has reiterated its Hold rating on Bio-Techne (TECH.US) and simultaneously reduced its target price to $54. This adjustment reflects the analyst's updated valuation for the company.
Evercore ISI Adjusts Price Target on Bio-Techne to $54 From $68, Maintains In Line Rating
Evercore ISI has revised its price target for Bio-Techne (NASDAQ: TECH) down to $54 from $68, while keeping an "In Line" rating on the stock. This adjustment reflects a change in the analyst's outlook for the biotechnology and medical research company. The article also lists recent news regarding Bio-Techne, including product expansions and presentations at healthcare conferences.
242,016 Shares in Bio-Techne Corp $TECH Acquired by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL has acquired a new stake of 242,016 shares in Bio-Techne Corp (NASDAQ:TECH) during the third quarter, valued at approximately $13.46 million. This acquisition represents about 0.16% of the biotechnology company, which recently reported Q3 earnings of $0.46 EPS against an expected $0.43 and revenue of $295.9 million. Bio-Techne maintains a consensus "Moderate Buy" rating from analysts with an average price target of $72.77.
Tudor Investment Corp Acquires $13.5M Stake in Bio-Techne
Tudor Investment Corp ET AL, a hedge fund, has acquired a new stake of 242,016 shares in Bio-Techne Corp (NASDAQ:TECH) during the third quarter, valued at approximately $13.5 million. This investment signifies confidence in Bio-Techne's growth potential within the biotechnology sector and indicates broader institutional interest in the company. The hedge fund now holds 0.16% ownership of the biotechnology company.
Exosomes Market Evolution (2026) | Nano Vesicles, Liquid Biopsy, Oncology Research & Biotech Investments | Top Companies 2026 - Miltenyi Biotec, Novus Biologicals, Capital Biosciences, and Bio Techne
DataM Intelligence has released a new research report on the Exosomes Market, highlighting its projected growth between 2026 and 2033. The report offers in-depth insights into market dynamics, segmentation, and includes recent industry developments and mergers & acquisitions. Key players listed include Thermo Fisher Scientific Inc., Qiagen, Beckman Coulter, Inc., and Lonza, among others, with the market focusing on oncology, neurodegenerative diseases, and regenerative medicine applications.
Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. (TECH) saw its stock rise by 2.33% to $53.48 on Wednesday, outperforming competitors and marking its third consecutive day of gains. This surge occurred on a strong trading day for the overall stock market, with the S&P 500 Index closing up 0.72% and the Dow Jones Industrial Average gaining 0.48%.
Top Players and Market Competition in the In Situ Hybridization Industry
The in situ hybridization market is projected to reach $3.08 billion by 2030, growing at an 11.3% CAGR, driven by personalized medicine, AI-driven analysis, and genomic research. Key players like Thermo Fisher Scientific and Danaher Corporation are shaping the industry, with a focus on innovations such as Hybridization Chain Reaction RNA Chromogenic in situ Hybridization (HCR RNA-CISH). The market is segmented by product types, techniques, probe types, applications, and end-users, highlighting its specialized and evolving nature.
Global Factors Influencing the Rapid Evolution of the GMP Cell Therapy Consumables Market
The GMP cell therapy consumables market is projected to reach $73.96 billion by 2030, growing at a CAGR of 26.6% due to the commercialization of cell therapies, demand for GMP-compliant manufacturing, and regulatory oversight. Key players like Thermo Fisher Scientific and Sartorius AG are driving innovation, with strategic acquisitions like Sartorius's purchase of Polyplus enhancing market capabilities. Growth is further fueled by the development of GMP-compliant CD34+ hematopoietic stem cells and market segmentation into various product types, cell therapy types, process stages, and end-uses.
SG Americas Securities LLC Acquires 126,702 Shares of Bio-Techne Corp $TECH
SG Americas Securities LLC significantly increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 1,275.2% during Q4, now holding 136,638 shares valued at $8.04 million. Bio-Techne exceeded Q4 earnings expectations with EPS of $0.46 and revenue of $295.9 million. Analysts maintain a "Moderate Buy" rating with a consensus price target of $72.77, compared to the recent share price of $52.04.
Charles River Laboratories Stock: A Key Player in Drug Discovery Services for North American Investo
Charles River Laboratories International, Inc. (NYSE: CRL) is a cornerstone in the contract research organization (CRO) sector, providing essential research services for drug discovery and development. The company operates through three segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. It holds a strong competitive position with a market capitalization of $9.70 billion, offering North American investors defensive growth within healthcare allocations.
Bio-Techne’s New COMET Spatial Tools Might Change The Case For Investing In Bio-Techne (TECH)
Bio-Techne has expanded its COMET spatial biology portfolio with new SPYRE Focus Panels, Amplification Kits, and upgraded HORIZON software, which could significantly enhance automated, high-plex tissue analysis. This innovation strengthens Bio-Techne's position in high-content, automated analysis for complex diseases, aligning with precision medicine trends. Despite potential near-term risks from biotech funding and tariffs, these advancements could positively influence the company's investment narrative, offering a potential 45% upside to its current price according to some fair value estimates.
Bio-Techne Corp. stock outperforms competitors on strong trading day
Bio-Techne Corp. (TECH) stock rallied 2.14% to $52.04, outperforming the mixed market on Monday. The Dow Jones Industrial Average rose while the S&P 500 Index fell. The company's stock closed 27.88% below its 52-week high.
In-Depth Examination of Segments, Industry Developments, and Key Competitors in the Biobank Equipment Market
The biobank equipment market is projected to reach $6.5 billion by 2030, growing at a CAGR of 9.2%, driven by automation, AI integration, and the needs of regenerative medicine. Key trends include AI-powered sample management and IoT-enabled monitoring, with top players like Thermo Fisher Scientific and Merck KGaA leading innovation. The market is segmented by product type, sample type, storage system type, application areas, and end-user groups, with a focus on sustainable, automated solutions for secure and efficient biological sample preservation.
Is It Time To Revisit Bio-Techne (TECH) After Recent Share Price Weakness?
Bio-Techne (TECH) has experienced recent share price weakness, with declines over the past week, month, and year. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock is approximately 29.1% undervalued based on its projected future cash flows. However, its current P/E ratio of 98.34x is significantly higher than both the industry average and Simply Wall St's proprietary Fair Ratio, indicating it might be overvalued on that metric.
SPYRE Focus Panel launch fails to lift Bio-Techne stock amid pronounced bearish momentum
Bio-Techne (TECH) introduced new SPYRE Focus Panels and Amplification Kits to enhance its spatial biology capabilities, but this failed to improve its stock performance. The company's shares continue to exhibit strong bearish momentum, trading well below key moving averages and indicating oversold conditions. Analysts predict a trading range of $49.00 to $52.00 for the upcoming week, with a high probability of further decline if crucial support levels are breached.
Is It Time To Revisit Bio-Techne (TECH) After Recent Share Price Weakness?
Bio-Techne (TECH) has experienced significant share price weakness, with declines over the past week, month, and year. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 29.1%. However, its current P/E ratio of 98.34x is considerably higher than the industry average and Simply Wall St's Fair Ratio, indicating it is overvalued on that metric.
Fairvoy Private Wealth Trims Ameriprise Financial Stake
Fairvoy Private Wealth LLC significantly reduced its stake in Ameriprise Financial, Inc. (NYSE:AMP) by 90.4% in the fourth quarter of 2025, according to a recent SEC filing. The investment firm now holds only 612 shares, down from 6,370 shares, valuing its remaining position at $300,000. While the reasons for this substantial reduction were not disclosed, it suggests a possible shift in the firm's investment strategy or outlook on the financial services sector.
Fort Washington Investment Advisors Reduces Stake in Bio-Techne
Fort Washington Investment Advisors Inc. OH has reduced its position in Bio-Techne Corp (NASDAQ:TECH) by 30.9% in Q4 2025, selling 146,767 shares and now owning 327,553 shares valued at approximately $19.3 million. This move indicates a potential shift in the firm's investment strategy regarding the biotechnology company or the broader industry, with other major investors also adjusting their Bio-Techne holdings. The transaction was disclosed in a 13F report filed on March 28, 2026.
Fort Washington Investment Advisors Inc. OH Sells 146,767 Shares of Bio-Techne Corp $TECH
Fort Washington Investment Advisors Inc. OH reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 30.9% in the 4th quarter, selling 146,767 shares and holding 327,553 shares valued at $19.26 million. Despite this, other major institutions like Goldman Sachs and JPMorgan increased their positions, leading to an institutional ownership of 98.95%. Analysts maintain a "Moderate Buy" rating with a target price of $72.77 against the stock's recent price of $50.95, and Bio-Techne also exceeded quarterly EPS estimates and pays a $0.08 quarterly dividend.
Technical Reactions to TECH Trends in Macro Strategies
This article analyzes Bio-techne Corp (NASDAQ: TECH) using AI models, identifying positive near-term sentiment with a weak mid-term bias within a long-term strength context. It provides three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and support/resistance levels. The analysis highlights an elevated downside risk in the short term.
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne Stocks Trade Down, What You Need To Know
Several medical and research equipment company stocks, including CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne, experienced declines in the afternoon trading session. This drop was attributed to investor uncertainty stemming from the U.S.-Iran conflict and upcoming policy deadlines, negatively impacting major indices like the S&P 500 and Dow Jones. Waters Corporation, in particular, saw its shares trade down, despite a previous significant merger announcement, with its stock currently 29.6% below its 52-week high.
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne stocks trade down, what you need to know
This article reports on several medical technology and life sciences companies whose stocks traded down. The companies mentioned are CONMED (CNMD), Bruker (BRKR), Waters Corporation (WAT), Avantor (AVTR), and Bio-Techne (TECH). The article does not provide specific reasons for the stock declines but indicates that investors may want to investigate further.
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne Stocks Trade Down, What You Need To Know
Several stocks, including CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne, experienced declines as major indices fell due to escalating uncertainty surrounding the U.S.-Iran conflict and Trump administration policy deadlines. The market's reaction, amplified by concerns of prolonged conflict and rising oil prices, was reflected in a decline in consumer confidence. Despite the widespread dip, the article suggests that significant price drops can create opportunities to acquire high-quality stocks.
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne Stocks Trade Down, What You Need To Know
Several prominent stocks, including CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne, experienced declines in the afternoon trading session. This downtrend is attributed to investor reactions to escalating uncertainty from the U.S.-Iran conflict and policy deadlines, which led to a sharp fall in major indices like the S&P 500 and Dow Jones Industrial Average. The article highlights that such market overreactions can present buying opportunities for high-quality stocks.
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne Stocks Trade Down, What You Need To Know
Several medical and research technology stocks, including CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne, experienced declines after major indices fell due to escalating uncertainty surrounding the U.S.-Iran conflict and Trump administration policy deadlines. The market reacted negatively to unpredictability and rising oil price concerns, leading to a dip in consumer confidence. While these individual stock drops are significant, the article suggests that such downturns can present buying opportunities for high-quality stocks.
Q4 Rundown: Sotera Health Company (NASDAQ:SHC) Vs Other Research Tools & Consumables Stocks
This article provides a Q4 rundown of Sotera Health Company (NASDAQ:SHC) and other research tools & consumables stocks, highlighting their financial performance and market reception. Sotera Health exceeded analysts' expectations with strong revenues and a positive outlook, despite a subsequent stock dip. The article also reviews top performers like Bio-Techne and notes the weakest, Mettler-Toledo, while touching on broader market shifts driven by AI and geopolitical events.
TECH Should I Buy
Bio-Techne Corp (TECH) is not currently a strong buy for long-term investors due to mixed signals, despite positive long-term growth potential. Technical indicators, hedge fund selling trends, and a lack of strong trading signals suggest holding off on a purchase. While analysts have raised price targets and maintain "Buy" ratings, concerns persist due to slight revenue and gross margin declines in Q2 2026.
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne Stocks Trade Down, What You Need To Know
Several stocks, including CONMED (NYSE: CNMD), Bruker (NASDAQ: BRKR), Waters Corporation (NYSE: WAT), Avantor (NYSE: AVTR), and Bio-Techne (NASDAQ: TECH), saw declines following a general market downturn. This dip was attributed to escalating uncertainty surrounding the U.S.-Iran conflict and policy deadlines from the Trump administration, amplifying market fears. The article notes that significant price drops can create opportunities for buying high-quality stocks.
Riverbridge Partners LLC Has $46.21 Million Stake in Bio-Techne Corp $TECH
Riverbridge Partners LLC reduced its stake in Bio-Techne (NASDAQ:TECH) by 13.3% in Q4, but still holds 785,788 shares valued at $46.21 million. Bio-Techne reported stronger-than-expected Q4 earnings with EPS of $0.46 and revenue of $295.88 million. Analysts have a "Moderate Buy" consensus rating for the company, with an average price target of $72.77.
Q4 Rundown: Sotera Health Company (NASDAQ:SHC) Vs Other Research Tools & Consumables Stocks
This article provides a Q4 rundown of research tools & consumables stocks, focusing on Sotera Health Company (SHC) and comparing its performance to peers like Bio-Techne (TECH), Mettler-Toledo (MTD), Revvity (RVTY), and Thermo Fisher (TMO). Sotera Health exceeded revenue and EPS guidance, performing strongly despite a subsequent stock dip. The sector as a whole met revenue expectations but has seen share price declines post-earnings.
Vanguard disaggregates holdings, reports 0% in Bio‑Techne (NASDAQ: TECH)
Vanguard has filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Bio-Techne (NASDAQ: TECH) common stock. This change follows an internal realignment effective January 12, 2026, which led certain Vanguard subsidiaries to report their holdings separately. The filing clarifies that this is a reporting adjustment due to organizational structure, not an indication of a market sale of Bio-Techne shares.
Q4 Research Tools & Consumables Earnings: Bio-Techne (NASDAQ:TECH) Earns Top Marks
Bio-Techne reported strong Q4 results, exceeding analyst expectations for revenue, though its stock saw an 18.5% decline post-reporting. The broader research tools & consumables sector had a satisfactory Q4, with revenues beating estimates by 1.2%, but share prices for many companies in the sector declined significantly. The article also reviews Q4 performance for other companies like Revvity, Mettler-Toledo, Sotera Health Company, and Agilent, highlighting varying results and market reactions amidst shifting market anxieties from AI disruption to geopolitical risks.
Bio-Techne Advances Spatial Biology with Modular Expansion of COMET Suite
Bio-Techne Corporation has expanded its COMET spatial biology solution portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits. These additions are designed to provide greater flexibility, higher sensitivity, and deeper insights for researchers studying complex tissue samples. The enhancements also include new features for HORIZON Image Analysis Software, further streamlining spatial biology workflows.
Bio Techne Reinvents 3D Stem Cell Research With Synthetic Scaffold
Bio-Techne Corporation has introduced Cultrex™ Synthetic Hydrogel, a synthetic extracellular matrix designed to standardize 3D stem cell and organoid research by reducing variability. This product aims to support reproducible and scalable research in areas like drug screening and personalized medicine, aligning with regulatory pushes for New Approach Methodologies (NAMs). The launch expands Bio-Techne's offerings in stem cell culture and coincides with a projected significant growth in the synthetic stem cells market, driven by advancements in regenerative medicine and demand for targeted therapies.
Bio-Techne expands spatial biology product portfolio
Bio-Techne Corporation has expanded its COMET spatial biology solution portfolio with the introduction of SPYRE Focus Panels and SPYRE Amplification Kits, alongside new features for its HORIZON Image Analysis Software. These additions aim to provide researchers with a more flexible, faster, and higher sensitivity workflow for achieving deeper insights in spatial biology. The company, which maintains a strong financial position with 19 consecutive years of dividend payments, also recently surpassed its Q2 fiscal year 2026 earnings and revenue forecasts, leading to increased price targets from analysts like Stifel, Argus, and TD Cowen.
Bio-Techne adds tools aimed at harder-to-detect tissue targets
Bio-Techne (NASDAQ: TECH) has expanded its COMET spatial biology portfolio with new SPYRE Focus Panels (Stroma and Vessel) and SPYRE Amplification Kits, alongside HORIZON image-analysis enhancements. These additions aim to increase sensitivity, accelerate setup, and offer flexibility for integrating lab antibodies within the COMET automated ecosystem. The goal is to streamline hyperplex tissue workflows, enabling deeper insights for research and preclinical studies, especially for low-abundance and challenging targets.
Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite
Bio-Techne has expanded its COMET™ spatial biology solution with new SPYRE™ Focus Panels (Stroma and Vessel) and SPYRE™ Amplification Kits. These additions enhance flexibility, sensitivity, and target detection, enabling deeper insights into complex tissue samples. The improvements to the COMET ecosystem, including HORIZON™ Image Analysis Software updates, aim to accelerate research and preclinical therapeutic development in spatial biology.
Bio-Techne Advances Spatial Biology with Modular Expansion of COMET Suite
Bio-Techne Corporation has expanded its COMET™ solution portfolio with the introduction of new SPYRE™ Focus Panels and SPYRE™ Amplification Kits, strengthening its modular spatial biology workflow. These additions aim to provide greater flexibility, sensitivity, and deeper insights for researchers analyzing complex tissue samples. The enhancements also include new features for the HORIZON™ Image Analysis Software to streamline tissue analysis, reinforcing Bio-Techne's commitment to advancing integrated and automated spatial biology.
Bio-Techne Sees Unusually Large Options Volume (NASDAQ:TECH)
Bio-Techne (NASDAQ:TECH) experienced unusually high options volume on Tuesday, with traders buying 10,021 put options, a 463% increase over average daily volume. This occurred as large institutions like Morgan Stanley and Massachusetts Financial Services significantly increased their stakes in the company, which reported strong quarterly earnings beating analyst estimates. The stock holds a consensus "Moderate Buy" rating with a target price of $72.77.
Global X Semiconductor ETF Guide (ASX: SEMI): What Is It All About?
The Global X Semiconductor ETF (ASX: SEMI) offers Australian investors concentrated exposure to global semiconductor companies, tracking the Solactive Global Semiconductor 30 Index. While it provides a direct way to invest in this critical sector and is easy to buy on the ASX, it is unhedged against currency fluctuations and represents a high-conviction, concentrated thematic holding rather than a diversified core portfolio component. Investors should consider its cyclical nature and focus on a single industry before including it in their portfolio.
Bio-Techne Corp. stock rises Monday, still underperforms market
Bio-Techne Corp. (TECH) saw its stock rise by 1.01% on Monday, closing at $52.00. Despite this gain, the company's performance underperformed the broader market, with both the S&P 500 and Dow Jones Industrial Average posting larger increases. The stock remains significantly below its 52-week high of $72.16 achieved in January.
Tudor Investment Corp ET AL Purchases Shares of 242,016 Bio-Techne Corp $TECH
Tudor Investment Corp ET AL recently acquired a new stake of 242,016 shares in Bio-Techne (NASDAQ:TECH) during the third quarter, valued at approximately $13.46 million. This purchase represents about 0.16% of the company. Bio-Techne has received positive attention from analysts, with a consensus rating of "Moderate Buy" and an average target price of $72.77, following recent target price increases by firms like Citigroup and UBS.
JPMorgan Chase Sells Stake in Bio-Techne Corp
JPMorgan Chase & Co. has significantly reduced its stake in Bio-Techne Corp by 46.6% during the third quarter of 2026, selling 633,738 shares. This divestment, which leaves JPMorgan Chase with 0.47% of Bio-Techne's shares, could indicate a shift in investor sentiment towards the biotechnology sector. Despite this, other major institutional investors have increased their positions in Bio-Techne, underscoring the company's continued appeal in the market.
JPMorgan Chase & Co. Sells 633,738 Shares of Bio-Techne Corp $TECH
JPMorgan Chase & Co. significantly reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 46.6%, selling 633,738 shares and retaining 725,085 shares valued at approximately $40.3 million. Despite this, other major institutions like Wellington Management Group, Norges Bank, and Durable Capital Partners LP increased their holdings, contributing to 98.95% institutional ownership. Bio-Techne recently surpassed EPS estimates with strong revenue and carries a "Moderate Buy" consensus rating with a target price of $72.77.
38,300 Shares in Bio-Techne Corp $TECH Purchased by Covea Finance
Covea Finance recently acquired a new stake of 38,300 shares in Bio-Techne (NASDAQ:TECH) during the fourth quarter, valued at approximately $2.25 million. This purchase is part of broader institutional interest, with several other investment firms also increasing their holdings in the biotechnology company. Bio-Techne reported strong quarterly earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating among analysts with a target price of $72.77.
After a Long Reset Period, Life Science Stocks Look Set to Rebound
Life science stocks, which have been under pressure since late 2022, are anticipated to experience a rebound. Morningstar expects profits in the sector to grow in the high single digits in 2026, with further acceleration possible from 2027 to 2030 due to upcoming catalysts.
TECH SEC Filings - Bio-Techne Corp 10-K, 10-Q, 8-K Forms
This page provides access to Bio-Techne Corporation's (TECH) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event disclosures (8-K), and insider trading forms. It offers detailed insights into the company's life sciences business, corporate governance, and executive compensation. The platform also provides AI-powered summaries of these documents for quick understanding.
Bio-Techne Corp (NASDAQ:TECH) Given Average Rating of "Moderate Buy" by Brokerages
Bio-Techne Corp (NASDAQ:TECH) has received a consensus "Moderate Buy" rating from fifteen research firms, with nine analysts recommending a "buy" and one a "strong buy." The average 12-month price target for the company's stock is $72.7692. The company recently reported strong quarterly earnings, exceeding analyst expectations, and announced a quarterly dividend of $0.08 per share.
